Superworth

Amphastar Pharmaceuticals price to book ratio AMPH

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
1.4×
10-year median
2.5×
Against its 10-year history
6th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.0× to 5.5×
Peer median
2.7×

Amphastar Pharmaceuticals' price to book ratio is 1.4× as of Oct 23, 2026.

That is below its ten-year median of 2.5×, lower than on 94% of days in the last ten years.

Over that time it ranged from 1.0× in May 2026 to 5.5× in Aug 2023.

The median for 10 large drugmakers of a similar size is 2.7×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.4×1.0×1.7×
20251.6×1.3×2.4×
20242.5×2.5×5.1×
20235.0×2.8×5.5×
20222.7×2.7×4.5×
20212.6×2.0×2.6×
20202.4×1.5×2.7×
20192.3×2.1×3.6×
20182.9×2.1×3.2×
20172.7×1.9×2.7×
20162.6×1.8×3.0×
20152.3×1.8×2.9×
20141.9×1.6×1.9×

Against its peers

Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
ABUSArbutus Biopharma3.2×
PCRXPacira BioSciences2.2×
ANABAnaptysbio138×
COLLCollegium Pharmaceutical2.4×
PAHCPhibro Animal Health4.1×
ANIPANI Pharmaceuticals2.8×
CRMDCorMedix1.3×
ZVRAZevra Therapeutics2.7×
IRWDIronwood Pharmaceuticalsn/m
Peer median2.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Amphastar Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.